122 related articles for article (PubMed ID: 9548486)
1. The DMB promoter: delineation, in vivo footprint, trans-activation, and trans-dominant suppression.
Ting JP; Wright KL; Chin KC; Brickey WJ; Li G
J Immunol; 1997 Dec; 159(11):5457-62. PubMed ID: 9548486
[TBL] [Abstract][Full Text] [Related]
2. The two novel MHC class II transactivators RFX5 and CIITA both control expression of HLA-DM genes.
Kern I; Steimle V; Siegrist CA; Mach B
Int Immunol; 1995 Aug; 7(8):1295-9. PubMed ID: 7495736
[TBL] [Abstract][Full Text] [Related]
3. Promoter-specific functions of CIITA and the MHC class II enhanceosome in transcriptional activation.
Masternak K; Reith W
EMBO J; 2002 Mar; 21(6):1379-88. PubMed ID: 11889043
[TBL] [Abstract][Full Text] [Related]
4. HLA-DMA and HLA-DMB gene expression functions through the conserved S-X-Y region.
Westerheide SD; Louis-Plence P; Ping D; He XF; Boss JM
J Immunol; 1997 May; 158(10):4812-21. PubMed ID: 9144496
[TBL] [Abstract][Full Text] [Related]
5. CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex.
Masternak K; Muhlethaler-Mottet A; Villard J; Zufferey M; Steimle V; Reith W
Genes Dev; 2000 May; 14(9):1156-66. PubMed ID: 10809673
[TBL] [Abstract][Full Text] [Related]
6. The transcription factor RFX protects MHC class II genes against epigenetic silencing by DNA methylation.
Seguín-Estévez Q; De Palma R; Krawczyk M; Leimgruber E; Villard J; Picard C; Tagliamacco A; Abbate G; Gorski J; Nocera A; Reith W
J Immunol; 2009 Aug; 183(4):2545-53. PubMed ID: 19620312
[TBL] [Abstract][Full Text] [Related]
7. CIITA-dependent and -independent class II MHC expression revealed by a dominant negative mutant.
Zhou H; Su HS; Zhang X; Douhan J; Glimcher LH
J Immunol; 1997 May; 158(10):4741-9. PubMed ID: 9144488
[TBL] [Abstract][Full Text] [Related]
8. Activation and transdominant suppression of MHC class II and HLA-DMB promoters by a series of C-terminal class II transactivator deletion mutants.
Chin KC; Li G; Ting JP
J Immunol; 1997 Sep; 159(6):2789-94. PubMed ID: 9300700
[TBL] [Abstract][Full Text] [Related]
9. Identification of class II transcriptional activator-induced genes by representational difference analysis: discoordinate regulation of the DN alpha/DO beta heterodimer.
Taxman DJ; Cressman DE; Ting JP
J Immunol; 2000 Aug; 165(3):1410-6. PubMed ID: 10903745
[TBL] [Abstract][Full Text] [Related]
10. X box-like sequences in the MHC class II region maintain regulatory function.
Gomez JA; Majumder P; Nagarajan UM; Boss JM
J Immunol; 2005 Jul; 175(2):1030-40. PubMed ID: 16002703
[TBL] [Abstract][Full Text] [Related]
11. Regulation of major histocompatibility (MHC) class II human leukocyte antigen-DR alpha gene expression in thyrocytes by single strand binding protein-1, a transcription factor that also regulates thyrotropin receptor and MHC class I gene expression.
Balducci-Silano PL; Suzuki K; Ohta M; Saito J; Ohmori M; Montani V; Napolitano G; Shong M; Taniguchi SI; Pietrarelli M; Lavaroni S; Mori A; Singer DS; Kohn LD
Endocrinology; 1998 May; 139(5):2300-13. PubMed ID: 9564838
[TBL] [Abstract][Full Text] [Related]
12. Detection of aberrant transcription of major histocompatibility complex class II antigen presentation genes in chronic lymphocytic leukaemia identifies HLA-DOA mRNA as a prognostic factor for survival.
Souwer Y; Chamuleau ME; van de Loosdrecht AA; Tolosa E; Jorritsma T; Muris JJ; Dinnissen-van Poppel MJ; Snel SN; van de Corput L; Ossenkoppele GJ; Meijer CJ; Neefjes JJ; Marieke van Ham S
Br J Haematol; 2009 May; 145(3):334-43. PubMed ID: 19245431
[TBL] [Abstract][Full Text] [Related]
13. Human MHC class II gene transcription directed by the carboxyl terminus of CIITA, one of the defective genes in type II MHC combined immune deficiency.
Zhou H; Glimcher LH
Immunity; 1995 May; 2(5):545-53. PubMed ID: 7749985
[TBL] [Abstract][Full Text] [Related]
14. Different levels of control prevent interferon-gamma-inducible HLA-class II expression in human neuroblastoma cells.
Croce M; De Ambrosis A; Corrias MV; Pistoia V; Occhino M; Meazza R; Giron-Michel J; Azzarone B; Accolla RS; Ferrini S
Oncogene; 2003 Oct; 22(49):7848-57. PubMed ID: 14586411
[TBL] [Abstract][Full Text] [Related]
15. Class II transactivator promoter activity is suppressed through regulation by a trophoblast noncoding RNA.
Geirsson A; Paliwal I; Lynch RJ; Bothwell AL; Hammond GL
Transplantation; 2003 Jul; 76(2):387-94. PubMed ID: 12883198
[TBL] [Abstract][Full Text] [Related]
16. A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients.
Masternak K; Barras E; Zufferey M; Conrad B; Corthals G; Aebersold R; Sanchez JC; Hochstrasser DF; Mach B; Reith W
Nat Genet; 1998 Nov; 20(3):273-7. PubMed ID: 9806546
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of MHC class II expression through inhibition of CIITA transcription by lytic transactivator Zta during Epstein-Barr virus reactivation.
Li D; Qian L; Chen C; Shi M; Yu M; Hu M; Song L; Shen B; Guo N
J Immunol; 2009 Feb; 182(4):1799-809. PubMed ID: 19201831
[TBL] [Abstract][Full Text] [Related]
18. Long distance control of MHC class II expression by multiple distal enhancers regulated by regulatory factor X complex and CIITA.
Krawczyk M; Peyraud N; Rybtsova N; Masternak K; Bucher P; Barras E; Reith W
J Immunol; 2004 Nov; 173(10):6200-10. PubMed ID: 15528357
[TBL] [Abstract][Full Text] [Related]
19. HLA class II expression in uninducible hepatocarcinoma cells after transfection of AIR-1 gene product CIITA: acquisition of antigen processing and presentation capacity.
Sartoris S; Valle MT; Barbaro AL; Tosi G; Cestari T; D'Agostino A; Megiovanni AM; Manca F; Accolla RS
J Immunol; 1998 Jul; 161(2):814-20. PubMed ID: 9670958
[TBL] [Abstract][Full Text] [Related]
20. Major histocompatibility class II HLA-DR alpha gene expression in thyrocytes: counter regulation by the class II transactivator and the thyroid Y box protein.
Montani V; Taniguchi SI; Shong M; Suzuki K; Ohmori M; Giuliani C; Napolitano G; Saji M; Fiorentino B; Reimold AM; Ting JP; Kohn LD; Singer DS
Endocrinology; 1998 Jan; 139(1):280-9. PubMed ID: 9421426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
